Evidence map›Paper›PMID 40576899›Full record

ArticleAnnals of surgical oncology2025

Accuracy of Breast MRI for Surgical Planning After Neoadjuvant Therapy for Patients with Invasive Lobular Carcinoma.

Anna Vertido, Tesia McKenzie, Alisha Othieno, Astrid Quirarte, Mandeep Kaur, Mary Kathryn Abel, Maggie Chung, Amie Y Lee, Rita A Mukhtar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anna VertidoDivision of Surgical Oncology, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Tesia McKenzieDivision of Breast Surgery, Riverview Medical Center, Hackensack Meridian Health, Shrewsbury, NJ, USA.
Alisha OthienoDepartment of Obstetrics and Gynecology, Kaiser Permanente Roseville Medical Center, Roseville, CA, USA.
Astrid QuirarteDivision of Surgical Oncology, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
Mandeep KaurSchool of Medicine, University of California San Francisco, San Francisco, CA, USA.
Mary Kathryn AbelDepartment of Obstetrics and Gynecology, Brigham and Women's Hospital, Massachusetts General Hospital, Boston, MA, USA.
Maggie ChungDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Amie Y LeeDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Rita A MukhtarDivision of Surgical Oncology, Department of Surgery, University of California San Francisco, San Francisco, CA, USA. Rita.Mukhtar@ucsf.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInvasive lobular carcinoma (ILC) is the second most common subtype of breast cancer, comprising 10-15% of cases. Due to its diffuse growth pattern, conventional imaging techniques have decreased sensitivity for ILC. While breast magnetic resonance imaging (MRI) is often recommended for ILC, its accuracy following neoadjuvant therapy is unknown. We evaluated the accuracy of post-treatment MRI and examined the impact on surgical outcomes. PATIENTS AND

methodsWe retrospectively analyzed 129 patients with ILC who underwent neoadjuvant chemotherapy (NAC) or endocrine therapy (NET) and had post-treatment MRI. We considered a 0.5 cm difference between longest tumor diameter on MRI and pathologic tumor size to be discrepant. Tumor imaging phenotype was categorized as mass, non-mass enhancement (NME), or mass + NME. We evaluated concordance between imaging and pathology by tumor phenotype and associations with positive margin rates using Stata 18.0.

resultsPost-treatment MRI underestimated tumor size in 52.5% of cases, was concordant in 25.3%, and overestimated in 22.2%. The presence of NME was associated with a higher rate of tumor size underestimation (62.5% versus 39.5% for mass only, p = 0.023); mean underestimation was 3.4 cm in those with NME. Underestimation was associated with higher positive margin rates following breast-conserving surgery (p = 0.018). Finally, among patients with complete imaging response on MRI, 93.3% had residual invasive disease on pathology.

conclusionsFollowing neoadjuvant therapy, post-treatment MRI frequently underestimates tumor size in ILC, particularly in tumors with NME. Surgeons should consider these imaging limitations when planning resection, which could improve surgical outcomes.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarcinoma, LobularMagnetic Resonance ImagingNeoadjuvant TherapyAdultAgedCarcinoma, Ductal, BreastChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm InvasivenessPrognosisRetrospective Studies

Identifiers

PMID40576899
PMCPMC12534223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.